본문 바로가기
KERD
논문KCI 등재

Responsiveness of CPT-11 in Respect to hMLH1 and hMSH2 Protein Expression in the Primary Colorectal Cancer

Tae Won Kim|Hee Cheol Kim|Chang Sik Yu|Jung Sun Kim|Heung Moon Chang|Jong Hoon Kim|Jin Cheon Kim|In Ja Park|Jea Hwan Lee
대한암학회 (Korean Cancer Association)|2004.12|Cancer Research and Treatment|제36권 제6호|pp. 360-366

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류의학일반

초록

Abstract

Purpose: The aim of this study was to evaluate the responsiveness to CPT-11 with respect to hMLH1 and hMSH2 protein expressions in primary colorectal tumors. Material and Methods: 91 patients with colorectal cancer treated having undergone surgery and postoperative CPT-11-based adjuvant chemotherapy, between 1997 and 2002, were prospectively recruited. Tumor samples were immunohistochemically analyzed for the expressions of hMLH1, hMSH2, p53 and CEA proteins. Results: Of the 91 tumors, 6 (6.6%) and 4 (4.4%) showed loss of hMLH1 and hMSH2 protein expressions, respectively. The response rate of patients with tumors not expressing either hMLH1 or hMSH2 was higher than that of those expressing either of these proteins (p=0.026). Patients with tumors not expressing hMLH1 showed a significantly better response to CPT-11 (p=0.04). The responsiveness was not associated with the expressions of hMSH2, p53 or CEA. There were no correlations between drug toxicity and the expressions of hMLH1, hMSH2 or p53. The overall survival was better in patients responsive to CPT-11-based chemotherapy compared to non-responders. Conclusion: The immunohistochemical determination of loss of hMLH1 and hMSH2 expressions may be used in determining the responsiveness to CPT-11-based chemotherapy. Our results suggest that hMLH1 protein expression may be a predictor for CPT-11 responsiveness in patients with colorectal cancer. (Cancer Res Treat. 2004;36:360-366)

참고문헌 (24)

  1. "Estimates of the worldwidemortality from eighteen major cancers in 1985 Implicationsfor prevention and projections of future burden", pp.891~903 (1993)
  2. "The chemotherapy of colon cancercan no longer be ignored", 29a, pp.2077~9 (1993)
  3. "Current status of colorectal cancer: CPT-11(irinotecan) a therapeutic innovation", 32, pp.1~8 (1996)
  4. "Irinotecan is an active agent in untreated patientswith metastatic colorectal cancer", 14, pp.709~715 (1996)
  5. "Irinotecan in the treatment of colorectal cancer:clinical overview", 19, pp.1501~1518 (2001)
  6. "Phase II study of irinotecan,5-fluorouracil,and leucovorinin relapsed or metastatic colorectal cancer as first-line therapy", 36, pp.235~239 (2004)
  7. "Mismatch repair defects in cancer", 10, pp.157~161 (2000)
  8. "Microsatellite instability in human cancer a prognostic marker for chemotherapy?", 246, pp.1~10 (1999)
  9. "Distribution of carcinoembryonic antigen and biologicbehavior in colorectal carcinoma", 42, pp.640~648 (1999)
  10. "WHO handbook for reporting results of cancer treatment", pp.48~ (1979)
  11. "version 2.0", pp.1~80 (1999), NCI-NIH National Cancer Institute
  12. "Tumor microsatellite instability and clinical outcomein young patients with colorectal cancer", 342, pp.69~77 (2000)
  13. "Microsatellite instability and the clinicopathological"
  14. "Tumor site, sex,and survival in colorectal cancer", 356, pp.858~ (2000)
  15. "Association of tumor site and sex with survival benefit fromadjuvant chemotherapy in colorectal cancer", 355, pp.1745~1750 (2000)
  16. "Defective mismatchbinding and a mutator phenotype in cells tolerant toDNA damage", 15, pp.652~4 (1993)
  17. "The role of DNA mismatch repair in platinum drug resistance", 56, pp.4881~4886 (1996)
  18. "Sensitivity to CPT-11 of xenograftedhuman colorectal cancers as a function of microsatelliteinstability and p53 status", 82, pp.913~923 (2000)
  19. "Microsatellite instability is a predictive factor of thetumor response to irinotecan in patients with advanced colorectalcancer", 63, pp.5738~5744 (2003)
  20. "Immunohistochemistry for hMLH1 and hMSH2:a practicaltest for DNA mismatch repair-deficient tumors", 23, pp.1248~1255 (1999)
  21. "Immunohistochemirstryfor MSH2 and MLH1: a method for identifying mismatchrepair deficient colorectal cancer", 54, pp.484~487 (2001)
  22. "Methylation ofthe hMLH1 and hMSH2 promoter in early-onset sporadiccolorectal carcinomas with microsatellite instability", 18, pp.196~202 (2003)
  23. "Repair of double-strand breaks by homologousrecombination in mismatch repair-defective mammaliancells", 21, pp.2671~2682 (2001)
  24. "The results of colorectal cancer treatment by p53 status: treatment-specific overview", 44, pp.322~333 (2001)

관련 논문AI추천

Microsatellite Instability and Mismatch Repair Protein (hMLH1, hMSH2) Expression in Intrahepatic Cholangiocarcinoma강윤경, 김우호대한병리학회 · Journal of Pathology and Translational Medicine2005 · 제39권 제1호Thymidylate Synthase, Thymidine Phosphorylase, VEGF and p53 Protein Expression in Primary Colorectal Cancer for Predicting Response to 5-fluorouracil-based ChemotherapyChan-Kum Park, Ho-Suk Oh, Il-Young Choi, In-Soon Kim, Jung-Hye Choi, Kang-Hong Lee, Kang-Won Song, Myung-Ju Ahn, Young-Yeul Lee대한암학회 · Cancer Research and Treatment2005 · 제37권 제4호Comparison of the Mismatch Repair System between Primary and Metastatic Colorectal Cancers Using Immunohistochemistry강영진, 김어진, 김주영, 김철환, 안보경, 이영석, 이유진, 이은정, 이정현, 정지윤, 채양석대한병리학회 · Journal of Pathology and Translational Medicine2017 · 제51권 제2호Comparison of WHO and RECIST Criteria for Response in Metastatic Colorectal Carcinoma이강홍, 최정혜, Hyan-Chul Rhim, In-Soon Kim, Jin-Woo Kim, Myung-Ju Ahn, Young-Yeul Lee대한암학회 · Cancer Research and Treatment2005 · 제37권 제5호Prognostic Significance of CpG Island Methylator Phenotype in Colorectal Cancer주영은거트앤리버 소화기연관학회협의회 · Gut and Liver2015 · 제9권 제2호Expression of Cyclooxygenase-2 and its Relationship to p53 Accumulation in Colorectal Cancers김경종, 민영돈, 유소연, 이태범, 임승철, 최철희연세대학교의과대학 · Yonsei Medical Journal2007 · 제48권 제3호

이 간행물의 다른 논문 (9건)

Preoperative Concurrent Chemoradiotherapy with Oral Fluoropyrimidine in Locally Advanced Rectal Cancer: How Good Is Good Enough ?Hyun Cheol Chungpp. 341-342HIF-1alpha: a Valid Therapeutic Target for Tumor Therapy이현승, 홍순선, 김규원pp. 343-353Prospective Phase II Study of Preoperative Chemoradiation with Capecitabine in Locally Advanced Rectal CancerSeong Soo Shin, Sang-wook Lee, Min Hee Ryu, Jin Cheon Kim, Jong Hoon Kim, Heung Moon Chang, Yoon-Koo Kang, Hee Cheol Kim, Eun Kyung Choi, Seung Do Ahn, Chang Sik Yu, Tae Won Kim, Jin-hong Parkpp. 354-359The Efficacy of Docetaxel and Cisplatin Combination Chemotherapy for the Treatment of Advanced Gastric Cancer after Failing to 5-Fluorouracil Based Chemotherapy송선교, 이경희, 현명수, 김상운, 김민경, Sang-Joon Shin, Sung-Hwa Bae, Hun-Mo Ryoopp. 367-371Open-label, Randomized Comparison of the Efficacy of Intravenous Dolasetron Mesylate and Ondansetron in the Prevention of Acute and Delayed Cisplatin-induced Emesis in Cancer Patients최인실, 김노경, Sang-Il Kim, 임석아, 박숙련, 김진수, 방영주, Ji Yeon Baek, 김동완, 허대석, 김태유pp. 372-376
원문 보기